Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Edesa Biotech, Inc. - Common Shares (NQ:EDSA)

0.8070 -0.0959 (-10.62%)
Streaming Delayed Price Updated: 3:53 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edesa Biotech, Inc. - Common Shares

< Previous 1 2 3 4 5 Next >
News headline image
Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech’s ARDS Drug
Via ACCESSWIRE
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday! 
Via InvestorPlace
News headline image
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance... 
Via Benzinga
News headline image
Why Comtech Telecommunications Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗
Gainers Oblong, Inc. (NASDAQ: OBLG) shares rose 295.7% to $1.16 in pre-market trading. 
Via Benzinga
News headline image
Edesa Biotech's Dermatitis Study Data Fails To Cheer Investors ↗
 
Via Benzinga
News headline image
Why Belden Shares Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Sigma Additive Solutions, Inc. (NASDAQ: SASI) shares jumped 196% to $7.34 after the company announced the signing of a definitive agreement for the acquisition of NextTrip Holdings, Inc. 
Via Benzinga
News headline image
Why Is Infectious Disease Player Edesa Biotech Stock Soaring Today? ↗
Edesa Biotech Inc (NASDAQ: EDSA) has secured a commitment of up to C$23 million from the Government of Canada for a pivotal Phase 3 clinical study of the company's first-in-class therapeutic... 
Via Benzinga
News headline image
Edesa Biotech Secures $10 Million Credit Facility with Company Founder
Via ACCESSWIRE
News headline image
Why InMode Shares Are Trading Lower By 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government
Via ACCESSWIRE
News headline image
Edesa Biotech Announces One-for-Seven Reverse Share Split
Via ACCESSWIRE
News headline image
Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant... 
Via Benzinga
News headline image
Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate
Via ACCESSWIRE
News headline image
Edesa Biotech Reports Fiscal Third Quarter 2023 Results
Via ACCESSWIRE
News headline image
Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference
Via ACCESSWIRE
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday! 
Via InvestorPlace
News headline image
Edesa Biotech's COVID-19 Candidate Restraints Inflammation From Influenza, Other Pathogens In Preclinical Studies ↗
Edesa Biotech Inc (NASDAQ: EDSA) released findings from an in vitro study involving its monoclonal antibody candidate, paridiprubart.  
Via Benzinga
News headline image
Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens
Via ACCESSWIRE
News headline image
Edesa Biotech Appoints Biotech Deal Veteran to CFO Role
Via ACCESSWIRE
News headline image
Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results
Via ACCESSWIRE
News headline image
Edesa Biotech to Participate in Swiss Biotech Day
Via ACCESSWIRE
News headline image
The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate
Via ACCESSWIRE
News headline image
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference
Via ACCESSWIRE
News headline image
Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting
Via ACCESSWIRE
News headline image
Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study
Via ACCESSWIRE
News headline image
Edesa Biotech Reports Fiscal 1st Quarter 2023 Results
Via ACCESSWIRE
News headline image
Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study
Via ACCESSWIRE
News headline image
Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket ↗
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) rose 41.5% to $0.3255 in pre-market trading after gaining 8% on Tuesday. 
Via Benzinga
News headline image
Nasdaq Edges Higher; Neovasc Shares Jump ↗
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Tuesday. 
Via Benzinga
News headline image
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.